Paris J, Botella J, Fournau P, Bonnet P, Thevenot R
Laboratoires Théramex, Monte-Carlo, Principauté de Monaco.
J Pharmacol Exp Ther. 1987 Oct;243(1):288-91.
19-Norprogesterone (19-NOR-P) is a potent progestagen in mammals by s.c. injection, but is almost inactive when given p.o. In the rat, 19-NOR-P also shows marked salt-retaining and hypertensive effects, consistent with its high affinity for mineralocorticoid receptors (MR). We synthetized recently some p.o. active 19-NOR-P derivatives, and have examined the extent to which the structural changes made on the parent compound can modify the affinity for MR and the salt-retaining potency. Compared with aldosterone, 19-NOR-P has a 47% affinity for rat renal cytosolic MR, decreasing to 13% with alpha-hydroxylation on C-17 (17 alpha-OH-19-NOR-P). The addition of a methyl group combined with the formation of a double bond at C-6 led to nomegestrol, the relative affinity of which was 1.2%. Binding was almost abolished completely (0.23%) by acetylation of the 17 alpha-OH group (nomegestrol-acetate). A single s.c. injection of 19-NOR-P, 20 micrograms/animal, induced a marked decline of [Na+]/[K+] ratio in urine of adrenalectomized male rats. The antinatriuretic effect was still observed after a 11-day period of daily administrations of the same dosage. 17 alpha-OH-19-NOR-P decreased the [Na+]/[K+] ratio only at a high p.o. dose (2500 micrograms/animal). NOM-Ac did not affect the [Na+]/[K+] ratio after a single s.c. or p.o. administration, but increased it at the end of a 11-day p.o. treatment. Thus, the chemical modifications that lead to potent p.o. active progestins derived from 19-NOR-P induce stepwise reductions in the affinity for MR and of the mineralocorticoid effects of the parent compound.
19-去甲孕酮(19-NOR-P)通过皮下注射时是哺乳动物体内一种强效的孕激素,但口服时几乎无活性。在大鼠中,19-NOR-P还表现出明显的保盐和高血压作用,这与其对盐皮质激素受体(MR)的高亲和力一致。我们最近合成了一些口服活性的19-NOR-P衍生物,并研究了对母体化合物进行的结构改变在多大程度上能够改变对MR的亲和力以及保盐效力。与醛固酮相比,19-NOR-P对大鼠肾胞质MR的亲和力为47%,在C-17位进行α-羟基化(17α-OH-19-NOR-P)后降至13%。在C-6位添加一个甲基并形成双键得到诺美孕酮,其相对亲和力为1.2%。17α-OH基团乙酰化(诺美孕酮醋酸酯)后结合几乎完全消失(0.23%)。对去肾上腺雄性大鼠单次皮下注射19-NOR-P,20微克/只,可导致尿中[Na⁺]/[K⁺]比值显著下降。在每日给予相同剂量11天后仍可观察到利钠作用。17α-OH-19-NOR-P仅在高口服剂量(2500微克/只)时降低[Na⁺]/[K⁺]比值。单次皮下或口服给予诺美孕酮醋酸酯后对[Na⁺]/[K⁺]比值无影响,但在口服治疗11天后会使其升高。因此,导致源自19-NOR-P的强效口服活性孕激素的化学修饰会使对MR的亲和力以及母体化合物的盐皮质激素作用逐步降低。